Cellular Stemness Maintenance of Human Adipose-Derived Stem Cells on ZnO Nanorod Arrays.
Kong Y., Ma B., Liu F., Chen D., Zhang S., Duan J.
Laboratory Study, published in Small (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Small (2019)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 31738003
- DOI
- 10.1002/smll.201904099
- Citations
- 22
Abstract (original English)
Ever-growing tissue regeneration and other stem cell therapies cause pressing need for large population of self-renewable stem cells. However, stem cells gradually lose their stemness after long-term in vitro cultivation. In this study, a ZnO nanorod (ZnO NR) array is used to maintain the stemness of human adipose-derived stem cells (hADSCs). The results prove that after culturing hADSCs on ZnO NRs for 3 weeks, the stemness genes and protein expression level are higher than that on culture plates and ZnO film. ZnO NRs can maintain stemness of hADSCs without inhibiting the cell proliferation and oriented differentiation capabilities. KLF4 (Kruppel-like factor 4) is a Zn 2+ -binding gene that plays a vital role in cell proliferation and differentiation. Sustained Zn 2+ release and the increased expression of KLF4 can be detected, suggesting that ZnO NRs have efficiently released Zn 2+ for stemness maintenance. Taken together, the nanotopography of ZnO NRs and the Zn 2+ release synergistically facilitate stemness maintenance. This study has provided a powerful tool for directing cell fate, maintaining stemness, and realizing the expansion of stem cells in vitro, which will open a new route for the manufacture of large populations of stem cells and fulfilling the growing demand for the cell therapy market.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.